{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:07:24Z","timestamp":1794607644471,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One of the pathways of the unfolded protein response, initiated by PKR-like endoplasmic reticulum kinase (PERK), is key to neuronal homeostasis in neurodegenerative diseases. PERK pathway activation is usually accomplished by inhibiting eIF2\u03b1-P dephosphorylation, after its phosphorylation by PERK. Less tried is an approach involving direct PERK activation without compromising long-term recovery of eIF2\u03b1 function by dephosphorylation. Here we show major improvement in cellular (ST<jats:italic>Hdh<\/jats:italic><jats:sup><jats:italic>Q111\/111<\/jats:italic><\/jats:sup>) and mouse (R6\/2) Huntington's disease (HD) models using a potent small molecule PERK activator that we developed, MK-28. MK-28 showed PERK selectivity <jats:italic>in vitro<\/jats:italic> on a 391-kinase panel and rescued cells (but not PERK\u2212\/\u2212 cells) from ER stress-induced apoptosis. Cells were also rescued by the commercial PERK activator CCT020312 but MK-28 was significantly more potent. Computational docking suggested MK-28 interaction with the PERK activation loop. MK-28 exhibited remarkable pharmacokinetic properties and high BBB penetration in mice. Transient subcutaneous delivery of MK-28 significantly improved motor and executive functions and delayed death onset in R6\/2 mice, showing no toxicity. Therefore, PERK activation can treat a most aggressive HD model, suggesting a possible approach for HD therapy and worth exploring for other neurodegenerative disorders.<\/jats:p>","DOI":"10.1038\/s41598-020-63899-4","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T10:02:52Z","timestamp":1587636172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["A novel specific PERK activator reduces toxicity and extends survival in Huntington's disease models"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2370-9819","authenticated-orcid":false,"given":"Javier","family":"Ganz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talya","family":"Shacham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Shenkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Eiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitai","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Iancovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luba","family":"Simhaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Da\u2019adoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamutal","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisim","family":"Perets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Barhum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Portnoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Offen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo Z.","family":"Lederkremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"63899_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/306234a0","volume":"306","author":"JF Gusella","year":"1983","unstructured":"Gusella, J. F. et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306, 234\u2013238 (1983).","journal-title":"Nature"},{"key":"63899_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross, C. A. et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10, 204\u2013216, https:\/\/doi.org\/10.1038\/nrneurol.2014.24 (2014).","journal-title":"Nat Rev Neurol"},{"key":"63899_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493\u2013506 (1996).","journal-title":"Cell"},{"key":"63899_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ng0893-398","volume":"4","author":"SE Andrew","year":"1993","unstructured":"Andrew, S. E. et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4, 398\u2013403, https:\/\/doi.org\/10.1038\/ng0893-398 (1993).","journal-title":"Nat Genet"},{"key":"63899_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrd.2018.133","volume":"17","author":"NS Caron","year":"2018","unstructured":"Caron, N. S., Dorsey, E. R. & Hayden, M. R. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nature reviews. Drug discovery 17, 729\u2013750, https:\/\/doi.org\/10.1038\/nrd.2018.133 (2018).","journal-title":"Nature reviews. Drug discovery"},{"key":"63899_CR6","doi-asserted-by":"publisher","first-page":"18167","DOI":"10.1074\/jbc.M109.018325","volume":"284","author":"A Carnemolla","year":"2009","unstructured":"Carnemolla, A. et al. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. The Journal of biological chemistry 284, 18167\u201318173, https:\/\/doi.org\/10.1074\/jbc.M109.018325 (2009).","journal-title":"The Journal of biological chemistry"},{"key":"63899_CR7","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1101\/gad.1673408","volume":"22","author":"ML Duennwald","year":"2008","unstructured":"Duennwald, M. L. & Lindquist, S. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev 22, 3308\u20133319 (2008).","journal-title":"Genes Dev"},{"key":"63899_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.brainres.2016.03.034","volume":"1648","author":"Y Jiang","year":"2016","unstructured":"Jiang, Y., Chadwick, S. R. & Lajoie, P. Endoplasmic reticulum stress: The cause and solution to Huntington's disease? Brain research 1648, 650\u2013657, https:\/\/doi.org\/10.1016\/j.brainres.2016.03.034 (2016).","journal-title":"Brain research"},{"key":"63899_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3753","volume":"4","author":"J Leitman","year":"2013","unstructured":"Leitman, J., Ulrich Hartl, F. & Lederkremer, G. Z. Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. Nature communications 4, 2753, https:\/\/doi.org\/10.1038\/ncomms3753 (2013).","journal-title":"Nature communications"},{"key":"63899_CR10","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.yexcr.2007.12.025","volume":"314","author":"S Reijonen","year":"2008","unstructured":"Reijonen, S., Putkonen, N., Norremolle, A., Lindholm, D. & Korhonen, L. Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp Cell Res 314, 950\u2013960, https:\/\/doi.org\/10.1016\/j.yexcr.2007.12.025 (2008).","journal-title":"Exp Cell Res"},{"key":"63899_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmolb.2019.00020","volume":"6","author":"T Shacham","year":"2019","unstructured":"Shacham, T., Sharma, N. & Lederkremer, G. Z. Protein Misfolding and ER Stress in Huntington's Disease. Front Mol Biosci 6, 20, https:\/\/doi.org\/10.3389\/fmolb.2019.00020 (2019).","journal-title":"Front Mol Biosci"},{"key":"63899_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/156652411794474419","volume":"11","author":"R Vidal","year":"2011","unstructured":"Vidal, R., Caballero, B., Couve, A. & Hetz, C. Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease. Curr Mol Med 11, 1\u201312 (2011).","journal-title":"Curr Mol Med"},{"key":"63899_CR13","doi-asserted-by":"publisher","first-page":"e90803","DOI":"10.1371\/journal.pone.0090803","volume":"9","author":"J Leitman","year":"2014","unstructured":"Leitman, J. et al. ER stress-induced eIF2-alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin. PloS one 9, e90803, https:\/\/doi.org\/10.1371\/journal.pone.0090803 (2014).","journal-title":"PloS one"},{"key":"63899_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1126\/science.1209038","volume":"334","author":"P Walter","year":"2011","unstructured":"Walter, P. & Ron, D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 334, 1081\u20131086 (2011).","journal-title":"Science"},{"key":"63899_CR15","doi-asserted-by":"publisher","first-page":"24881","DOI":"10.1074\/jbc.M004454200","volume":"275","author":"CY Liu","year":"2000","unstructured":"Liu, C. Y., Schroder, M. & Kaufman, R. J. Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J Biol Chem 275, 24881\u201324885, https:\/\/doi.org\/10.1074\/jbc.M004454200 (2000).","journal-title":"J Biol Chem"},{"key":"63899_CR16","doi-asserted-by":"publisher","first-page":"7198","DOI":"10.1128\/mcb.23.20.7198-7209.2003","volume":"23","author":"SB Cullinan","year":"2003","unstructured":"Cullinan, S. B. et al. Nrf2 Is a Direct PERK Substrate and Effector of PERK-Dependent Cell Survival. Molecular and Cellular Biology 23, 7198\u20137209, https:\/\/doi.org\/10.1128\/mcb.23.20.7198-7209.2003 (2003).","journal-title":"Molecular and Cellular Biology"},{"key":"63899_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mrfmmm.2004.06.056","volume":"569","author":"M Schroder","year":"2005","unstructured":"Schroder, M. & Kaufman, R. J. ER stress and the unfolded protein response. Mutat Res 569, 29\u201363, https:\/\/doi.org\/10.1016\/j.mrfmmm.2004.06.056 (2005).","journal-title":"Mutat Res"},{"key":"63899_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ncb3184","volume":"17","author":"C Hetz","year":"2015","unstructured":"Hetz, C., Chevet, E. & Oakes, S. A. Proteostasis control by the unfolded protein response. Nature cell biology 17, 829\u2013838, https:\/\/doi.org\/10.1038\/ncb3184 (2015).","journal-title":"Nature cell biology"},{"key":"63899_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.15252\/emmm.201606664","volume":"9","author":"J Bruch","year":"2017","unstructured":"Bruch, J. et al. PERK activation mitigates tau pathology in vitro and in vivo. EMBO molecular medicine 9, 371\u2013384, https:\/\/doi.org\/10.15252\/emmm.201606664 (2017).","journal-title":"EMBO molecular medicine"},{"key":"63899_CR20","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/hmg\/9.19.2799","volume":"9","author":"F Trettel","year":"2000","unstructured":"Trettel, F. et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9, 2799\u20132809 (2000).","journal-title":"Hum Mol Genet"},{"key":"63899_CR21","doi-asserted-by":"publisher","unstructured":"Wang, H., Blais, J., Ron, D. & Cardozo, T. Structural determinants of PERK inhibitor potency and selectivity. Chem Biol Drug Des 76, 480-495, https:\/\/doi.org\/10.1111\/j.1747-0285.2010.01048.x [doi] (2010).","DOI":"10.1111\/j.1747-0285.2010.01048.x"},{"key":"63899_CR22","doi-asserted-by":"publisher","first-page":"7193","DOI":"10.1021\/jm300713s","volume":"55","author":"JM Axten","year":"2012","unstructured":"Axten, J. M. et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem 55, 7193\u20137207, https:\/\/doi.org\/10.1021\/jm300713s (2012).","journal-title":"J Med Chem"},{"key":"63899_CR23","doi-asserted-by":"publisher","unstructured":"Guyenet, S. J. et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. Journal of visualized experiments: JoVE, https:\/\/doi.org\/10.3791\/1787 (2010).","DOI":"10.3791\/1787"},{"key":"63899_CR24","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1093\/hmg\/ddy152","volume":"27","author":"V Grande","year":"2018","unstructured":"Grande, V. et al. PERK inhibition delays neurodegeneration and improves motor function in a mouse model of Marinesco-Sjogren syndrome. Hum Mol Genet 27, 2477\u20132489, https:\/\/doi.org\/10.1093\/hmg\/ddy152 (2018).","journal-title":"Hum Mol Genet"},{"key":"63899_CR25","doi-asserted-by":"publisher","first-page":"206ra138","DOI":"10.1126\/scitranslmed.3006767","volume":"5","author":"JA Moreno","year":"2013","unstructured":"Moreno, J. A. et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Science translational medicine 5, 206ra138, https:\/\/doi.org\/10.1126\/scitranslmed.3006767 (2013).","journal-title":"Science translational medicine"},{"key":"63899_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.1201396","volume":"332","author":"P Tsaytler","year":"2011","unstructured":"Tsaytler, P., Harding, H. P., Ron, D. & Bertolotti, A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science (New York, N.Y.) 332, 91\u201394, https:\/\/doi.org\/10.1126\/science.1201396 (2011).","journal-title":"Science (New York, N.Y.)"},{"key":"63899_CR27","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1128\/MCB.23.16.5651-5663.2003","volume":"23","author":"HY Jiang","year":"2003","unstructured":"Jiang, H. Y. et al. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol 23, 5651\u20135663 (2003).","journal-title":"Mol Cell Biol"},{"key":"63899_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.molcel.2010.09.023","volume":"40","author":"G Kroemer","year":"2010","unstructured":"Kroemer, G., Marino, G. & Levine, B. Autophagy and the integrated stress response. Mol Cell 40, 280\u2013293, https:\/\/doi.org\/10.1016\/j.molcel.2010.09.023 (2010).","journal-title":"Mol Cell"},{"key":"63899_CR29","doi-asserted-by":"publisher","first-page":"e14295","DOI":"10.7554\/eLife.14295","volume":"5","author":"R Ishimura","year":"2016","unstructured":"Ishimura, R., Nagy, G., Dotu, I., Chuang, J. H. & Ackerman, S. L. Activation of GCN2 kinase by ribosome stalling links translation elongation with translation initiation. eLife 5, e14295, https:\/\/doi.org\/10.7554\/eLife.14295 (2016).","journal-title":"eLife"},{"key":"63899_CR30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","volume":"1792","author":"RJ Ferrante","year":"2009","unstructured":"Ferrante, R. J. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 1792, 506\u2013520, https:\/\/doi.org\/10.1016\/j.bbadis.2009.04.001 (2009).","journal-title":"Biochim Biophys Acta"},{"key":"63899_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/cne.20680","volume":"490","author":"EC Stack","year":"2005","unstructured":"Stack, E. C. et al. Chronology of behavioral symptoms and neuropathological sequela in R6\/2 Huntington's disease transgenic mice. J Comp Neurol 490, 354\u2013370, https:\/\/doi.org\/10.1002\/cne.20680 (2005).","journal-title":"J Comp Neurol"},{"key":"63899_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00702-013-1115-9","volume":"121","author":"S Skodda","year":"2014","unstructured":"Skodda, S., Schlegel, U., Hoffmann, R. & Saft, C. Impaired motor speech performance in Huntington's disease. J Neural Transm (Vienna) 121, 399\u2013407, https:\/\/doi.org\/10.1007\/s00702-013-1115-9 (2014).","journal-title":"J Neural Transm (Vienna)"},{"key":"63899_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/ana.410380602","volume":"38","author":"RL Albin","year":"1995","unstructured":"Albin, R. L. Selective neurodegeneration in Huntington's disease. Ann Neurol 38, 835\u2013836, https:\/\/doi.org\/10.1002\/ana.410380602 (1995).","journal-title":"Ann Neurol"},{"key":"63899_CR34","doi-asserted-by":"publisher","first-page":"e19965","DOI":"10.1371\/journal.pone.0019965","volume":"6","author":"S Pietropaolo","year":"2011","unstructured":"Pietropaolo, S., Delage, P., Cayzac, S., Crusio, W. E. & Cho, Y. H. Sex-dependent changes in social behaviors in motor pre-symptomatic R6\/1 mice. PLoS One 6, e19965, https:\/\/doi.org\/10.1371\/journal.pone.0019965 (2011).","journal-title":"PLoS One"},{"key":"63899_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","volume":"8","author":"K Sathasivam","year":"1999","unstructured":"Sathasivam, K. et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 8, 813\u2013822 (1999).","journal-title":"Hum Mol Genet"},{"key":"63899_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1399-0004.1985.tb00185.x","volume":"27","author":"LA Farrer","year":"1985","unstructured":"Farrer, L. A. Diabetes mellitus in Huntington disease. Clin Genet 27, 62\u201367 (1985).","journal-title":"Clin Genet"},{"key":"63899_CR37","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/S0140-6736(72)91092-6","volume":"1","author":"S Podolsky","year":"1972","unstructured":"Podolsky, S., Leopold, N. A. & Sax, D. S. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1, 1356\u20131358 (1972).","journal-title":"Lancet"},{"key":"63899_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/JHD-170253","volume":"6","author":"MT Montojo","year":"2017","unstructured":"Montojo, M. T., Aganzo, M. & Gonzalez, N. Huntington's Disease and Diabetes: Chronological Sequence of its Association. J Huntingtons Dis 6, 179\u2013188, https:\/\/doi.org\/10.3233\/JHD-170253 (2017).","journal-title":"J Huntingtons Dis"},{"key":"63899_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00221-005-2357-z","volume":"166","author":"MJ Hunt","year":"2005","unstructured":"Hunt, M. J. & Morton, A. J. Atypical diabetes associated with inclusion formation in the R6\/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res 166, 220\u2013229, https:\/\/doi.org\/10.1007\/s00221-005-2357-z (2005).","journal-title":"Exp Brain Res"},{"key":"63899_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/hmg\/ddi053","volume":"14","author":"M Bjorkqvist","year":"2005","unstructured":"Bjorkqvist, M. et al. The R6\/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet 14, 565\u2013574, https:\/\/doi.org\/10.1093\/hmg\/ddi053 (2005).","journal-title":"Hum Mol Genet"},{"key":"63899_CR41","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1126\/science.1101902","volume":"307","author":"M Boyce","year":"2005","unstructured":"Boyce, M. et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science (New York, N.Y.) 307, 935\u2013939, https:\/\/doi.org\/10.1126\/science.1101902 (2005).","journal-title":"Science (New York, N.Y.)"},{"key":"63899_CR42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.aaa4484","volume":"348","author":"I Das","year":"2015","unstructured":"Das, I. et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science (New York, N.Y.) 348, 239\u2013242, https:\/\/doi.org\/10.1126\/science.aaa4484 (2015).","journal-title":"Science (New York, N.Y.)"},{"key":"63899_CR43","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.cell.2018.06.030","volume":"174","author":"A Krzyzosiak","year":"2018","unstructured":"Krzyzosiak, A. et al. Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B. Cell 174, 1216\u20131228.e1219, https:\/\/doi.org\/10.1016\/j.cell.2018.06.030 (2018).","journal-title":"Cell"},{"key":"63899_CR44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1083\/jcb.153.5.1011","volume":"153","author":"I Novoa","year":"2001","unstructured":"Novoa, I., Zeng, H., Harding, H. P. & Ron, D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. The Journal of cell biology 153, 1011\u20131022 (2001).","journal-title":"The Journal of cell biology"},{"key":"63899_CR45","doi-asserted-by":"publisher","first-page":"e0135570","DOI":"10.1371\/journal.pone.0135570","volume":"10","author":"FG Vieira","year":"2015","unstructured":"Vieira, F. G. et al. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS. PloS one 10, e0135570, https:\/\/doi.org\/10.1371\/journal.pone.0135570 (2015).","journal-title":"PloS one"},{"key":"63899_CR46","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/nen.0000000000000224","volume":"74","author":"J Bruch","year":"2015","unstructured":"Bruch, J. et al. Early Neurodegeneration in the Brain of a Child Without Functional PKR-like Endoplasmic Reticulum Kinase. Journal of neuropathology and experimental neurology 74, 850\u2013857, https:\/\/doi.org\/10.1097\/nen.0000000000000224 (2015).","journal-title":"Journal of neuropathology and experimental neurology"},{"key":"63899_CR47","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1093\/hmg\/ddy297","volume":"27","author":"SH Yuan","year":"2018","unstructured":"Yuan, S. H. et al. Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress. Hum Mol Genet 27, 3951\u20133963, https:\/\/doi.org\/10.1093\/hmg\/ddy297 (2018).","journal-title":"Hum Mol Genet"},{"key":"63899_CR48","doi-asserted-by":"publisher","first-page":"e1672","DOI":"10.1038\/cddis.2015.49","volume":"6","author":"M Halliday","year":"2015","unstructured":"Halliday, M. et al. Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell death & disease 6, e1672, https:\/\/doi.org\/10.1038\/cddis.2015.49 (2015).","journal-title":"Cell death & disease"},{"key":"63899_CR49","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/brain\/awx074","volume":"140","author":"M Halliday","year":"2017","unstructured":"Halliday, M. et al. Repurposed drugs targeting eIF2&alpha;-P-mediated translational repression prevent neurodegeneration in mice. Brain: a journal of neurology 140, 1768\u20131783, https:\/\/doi.org\/10.1093\/brain\/awx074 (2017).","journal-title":"Brain: a journal of neurology"},{"key":"63899_CR50","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/J.NBD.2018.01.004","volume":"112","author":"G Mercado","year":"2018","unstructured":"Mercado, G. et al. Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease. Neurobiology of disease 112, 136\u2013148, https:\/\/doi.org\/10.1016\/J.NBD.2018.01.004 (2018).","journal-title":"Neurobiology of disease"},{"key":"63899_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00401-015-1487-z","volume":"130","author":"H Radford","year":"2015","unstructured":"Radford, H., Moreno, J. A., Verity, N., Halliday, M. & Mallucci, G. R. PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta neuropathologica 130, 633\u2013642, https:\/\/doi.org\/10.1007\/s00401-015-1487-z (2015).","journal-title":"Acta neuropathologica"},{"key":"63899_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2016.02.005","volume":"41","author":"W Yang","year":"2016","unstructured":"Yang, W. et al. Repression of the eIF2alpha kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease. Neurobiology of aging 41, 19\u201324, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.02.005 (2016).","journal-title":"Neurobiology of aging"},{"key":"63899_CR53","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2337\/diabetes.51.7.2301","volume":"51","author":"A Biason-Lauber","year":"2002","unstructured":"Biason-Lauber, A., Lang-Muritano, M., Vaccaro, T. & Schoenle, E. J. Loss of kinase activity in a patient with Wolcott-Rallison syndrome caused by a novel mutation in the EIF2AK3 gene. Diabetes 51, 2301\u20132305 (2002).","journal-title":"Diabetes"},{"key":"63899_CR54","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","volume":"234","author":"A Sali","year":"1993","unstructured":"Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234, 779\u2013815, https:\/\/doi.org\/10.1006\/jmbi.1993.1626 (1993).","journal-title":"J Mol Biol"},{"key":"63899_CR55","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47, 1739\u20131749, https:\/\/doi.org\/10.1021\/jm0306430 (2004).","journal-title":"J Med Chem"},{"key":"63899_CR56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27, 221\u2013234, https:\/\/doi.org\/10.1007\/s10822-013-9644-8 (2013).","journal-title":"J Comput Aided Mol Des"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63899-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63899-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63899-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:32:45Z","timestamp":1670319165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63899-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63899"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63899-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"22 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6875"}}